Vignati S - Search Results

1

Cellular and molecular consequences of peroxisome proliferator-activated receptor-gamma activation in ovarian cancer cells.

Vignati S, Albertini V, Rinaldi A, Kwee I, Riva C, Oldrini R, Capella C, Bertoni F, Carbone GM, Catapano CV. Vignati S, et al. Neoplasia. 2006 Oct;8(10):851-61. doi: 10.1593/neo.06433. Neoplasia. 2006. PMID: 17032502 Free PMC article.

2

Novel GC-rich DNA-binding compound produced by a genetically engineered mutant of the mithramycin producer Streptomyces argillaceus exhibits improved transcriptional repressor activity: implications for cancer therapy.

Albertini V, Jain A, Vignati S, Napoli S, Rinaldi A, Kwee I, Nur-e-Alam M, Bergant J, Bertoni F, Carbone GM, Rohr J, Catapano CV. Albertini V, et al. Among authors: vignati s. Nucleic Acids Res. 2006 Mar 29;34(6):1721-34. doi: 10.1093/nar/gkl063. Print 2006. Nucleic Acids Res. 2006. PMID: 16571899 Free PMC article.

3

Cyclin-dependent kinase inhibitor seliciclib shows in vitro activity in diffuse large B-cell lymphomas.

Lacrima K, Rinaldi A, Vignati S, Martin V, Tibiletti MG, Gaidano G, Catapano CV, Bertoni F. Lacrima K, et al. Among authors: vignati s. Leuk Lymphoma. 2007 Jan;48(1):158-67. doi: 10.1080/10428190601026562. Leuk Lymphoma. 2007. PMID: 17325859

4

Inactivation of Ret/Ptc1 oncoprotein and inhibition of papillary thyroid carcinoma cell proliferation by indolinone RPI-1.

Lanzi C, Cassinelli G, Cuccuru G, Zaffaroni N, Supino R, Vignati S, Zanchi C, Yamamoto M, Zunino F. Lanzi C, et al. Among authors: vignati s. Cell Mol Life Sci. 2003 Jul;60(7):1449-59. doi: 10.1007/s00018-003-2381-8. Cell Mol Life Sci. 2003. PMID: 12943231 Free PMC article.

5

Antisense oligonucleotide-mediated inhibition of hTERT, but not hTERC, induces rapid cell growth decline and apoptosis in the absence of telomere shortening in human prostate cancer cells.

Folini M, Brambilla C, Villa R, Gandellini P, Vignati S, Paduano F, Daidone MG, Zaffaroni N. Folini M, et al. Among authors: vignati s. Eur J Cancer. 2005 Mar;41(4):624-34. doi: 10.1016/j.ejca.2004.12.002. Epub 2005 Jan 20. Eur J Cancer. 2005. PMID: 15737568

6

Ribozyme-mediated inhibition of survivin expression increases spontaneous and drug-induced apoptosis and decreases the tumorigenic potential of human prostate cancer cells.

Pennati M, Binda M, Colella G, Zoppe' M, Folini M, Vignati S, Valentini A, Citti L, De Cesare M, Pratesi G, Giacca M, Daidone MG, Zaffaroni N. Pennati M, et al. Among authors: vignati s. Oncogene. 2004 Jan 15;23(2):386-94. doi: 10.1038/sj.onc.1207071. Oncogene. 2004. PMID: 14724567

7

Inositol pentakisphosphate promotes apoptosis through the PI 3-K/Akt pathway.

Piccolo E, Vignati S, Maffucci T, Innominato PF, Riley AM, Potter BV, Pandolfi PP, Broggini M, Iacobelli S, Innocenti P, Falasca M. Piccolo E, et al. Among authors: vignati s. Oncogene. 2004 Mar 4;23(9):1754-65. doi: 10.1038/sj.onc.1207296. Oncogene. 2004. PMID: 14755253

8

Association of MC1R variants with melanoma risk and interaction with sun exposure: An M-SKIP project.

Stefanaki I, D'Ecclesiis O, Vignati S, Gaeta A, Kypreou K, Caini S, Gandini S, Nagore E, Sera F, Botta F, Newton-Bishop J, Polsky D, Lazovich D, Kanetsky PA, Puig S, Gruis NA, Landi MT, Fargnoli MC, Stratigos A, Guida G, Ghiorzo P, Menin C, García-Borrón JC, Little J, Nan H, Raimondi S; M‐SKIP study group. Stefanaki I, et al. Among authors: vignati s. J Eur Acad Dermatol Venereol. 2024 Oct 19. doi: 10.1111/jdv.20380. Online ahead of print. J Eur Acad Dermatol Venereol. 2024. PMID: 39425518 No abstract available.

9

A Transcriptomic Analysis of Laryngeal Dysplasia.

Maffini F, Lepanto D, Chu F, Tagliabue M, Vacirca D, De Berardinis R, Gandini S, Vignati S, Ranghiero A, Taormina S, Rappa A, Cossu Rocca M, Alterio D, Chiocca S, Barberis M, Preda L, Pagni F, Fusco N, Ansarin M. Maffini F, et al. Among authors: vignati s. Int J Mol Sci. 2024 Sep 7;25(17):9685. doi: 10.3390/ijms25179685. Int J Mol Sci. 2024. PMID: 39273632 Free PMC article. Review.

10

Association between mpMRI detected tumor apparent diffusion coefficient and 5-year biochemical recurrence risk after radical prostatectomy.

Alessi S, Maggioni R, Luzzago S, Summers PE, Renne G, Zugni F, Belmonte M, Raimondi S, Vignati S, Mistretta FA, Di Meglio L, D'Ascoli E, Scarabelli A, Marvaso G, De Cobelli O, Musi G, Jereczek-Fossa BA, Curigliano G, Petralia G. Alessi S, et al. Among authors: vignati s. Radiol Med. 2024 Sep;129(9):1394-1404. doi: 10.1007/s11547-024-01857-0. Epub 2024 Jul 16. Radiol Med. 2024. PMID: 39014292

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

54 results

Search Page

Filters